Cargando…
Targeting CX3CR1 Suppresses the Fanconi Anemia DNA Repair Pathway and Synergizes with Platinum
SIMPLE SUMMARY: Chemotherapeutics exerting their antiproliferative actions by introducing DNA crosslinks, such as platinum drugs, are used to treat numerous cancers. Unfortunately, their therapeutic potential is limited due to adverse side effects and acquired resistance, the latter often associated...
Autores principales: | Lehto, Jemina, Huguet Ninou, Anna, Chioureas, Dimitrios, Jonkers, Jos, Gustafsson, Nina M. S. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8004634/ https://www.ncbi.nlm.nih.gov/pubmed/33810010 http://dx.doi.org/10.3390/cancers13061442 |
Ejemplares similares
-
PFKFB3 Inhibition Sensitizes DNA Crosslinking Chemotherapies by Suppressing Fanconi Anemia Repair
por: Ninou, Anna Huguet, et al.
Publicado: (2021) -
Platinum-based chemotherapy for pancreatic cancer: impact of mutations in the homologous recombination repair and Fanconi anemia genes
por: Emelyanova, Marina, et al.
Publicado: (2022) -
Mutated Fanconi anemia pathway in non-Fanconi anemia cancers
por: Shen, Yihang, et al.
Publicado: (2015) -
Fanconi Anemia: A Signal Transduction and DNA Repair
Pathway
por: Kupfer, Gary M.
Publicado: (2013) -
Regulation of the Fanconi Anemia DNA Repair Pathway by Phosphorylation and Monoubiquitination
por: Ishiai, Masamichi
Publicado: (2021)